ITMIG2021 – Program

Scientific Program

Program of

11th virtual ITMIG 2021 Annual Meeting

NOTE:

All hours are in EST (Eastern Standard Time)/EDT (Eastern Daylight Time)

Check the correct hour in your time zone!

TIME (EST/EDT)

EST = Eastern Standard Time

EDT = Eastern Daylight Time

FRIDAY, OCTOBER 15, 2021

08:30 – 11:30 EST/EDT

COMMITTEE AND WORKING GROUP MEETINGS

All participants and ITMIG members are welcome!

08:30 – 08:40 EST/EDT – Communication Committee, Malgorzata Szolkowska, The National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

08:40 – 08:50 EST/EDT – Finance Committee, Joshua Sonett, The Columbia University/New York-Presbyterian Hospital, New York City, USA

08:50 – 09:00 EST/EDT – Membership Committee, Paolo Mendogni, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

09:00 – 09:30 EST/EDT – Database Committee, Nicolas Girard, The Institut Curie, Paris, France, Usman Ahmad, Heart, Vascular and Thoracic Institute, the Cleveland Clinic, Cleveland, OH, USA

09:30 – 10:00 EST/EDT – Education Committee, Mirella Marino, IRCCS Regina Elena National Cancer Institute Rome, Italy

10:00 – 10:30 EST/EDT – Steering Committee, Nicolas Girard, The Institut Curie, Paris, France

10:30 – 11:00 EST/EDT – Thymic Carcinoma Working Group, Anja Roden, The Mayo Clinic Rochester, Rochester, MN, USA

11:00 – 11:30 EST/EDT – Mediastinal Working Group, Anja Roden, The Mayo Clinic Rochester, Rochester, MN, USA

11:30 – 11:45 EST/EDT

Break

11:45 – 12:45 EST/EDT

POSTER SESSION – Live Q&A

Posters will be available on conference platform a week before the conference

11:45-12:15 EST/EDT 

Poster # 3: Circulating EBV (cEBV) and metabolic imaging monitoring during therapy for thymic lymphoepithelioma-like carcinoma (tLELC ); A case study. Haim Biran, Department of Oncology, The Chaim Sheba Medical center, Ramat Gan, Israel affiliated to the Sackler School of Medicine, Tel Aviv University, Israel

Poster # 8: Synchronous thymic and breast malignancies: a single institutional experienceRocco Morra, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy

Poster # 10: Incidental discovery of thymic masses during Sars-Cov-2 infection. Roberto Buonaiuto, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy

Poster #11: Rescue Chemotherapy in a Patient with Thymoma and Severe Symptoms of Myasthenia Gravis. A case report. Magdalena Knetki-Wróblewska, Department of Lung Cancer and Chest Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Poster #14: A Case of Li-Fraumeni Syndrome Associated Thymoma. Sara Kuruvilla, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

Poster #20: SARS-CoV2 infection in patient with thymoma: presentation of two cases. Mirella Marino, Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy

12:15-12:45 EST/EDT 

Poster #5: Post operative management and outcome of high risk thymoma and thymic carcinoma following curative intent surgery. A single centre experienceMaggie Harris, The Christie NHS Foundation Trust, Manchester, UK

Poster # 9: Pitfalls in mediastinal masses diagnosis. Aldo Caltavituro, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy

Poster #17: Oncological outcomes of robotic extended thymectomy for early stage thymoma compared to sternotomy: a retrospective single centre institution analysis. Filippo Tommaso Gallina, Thoracic Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Poster #18: Advances in mediastinal tumors diagnosis: J. Rosai, a master of Pathology, and the value of morphology and related disciplines. Lucia Anemona, Department of Experimental Medicine, Faculty of Medicine, Tor Vergata University, Rome, Italy

Poster #19: Extended subxiphoid thymectomy for a large B3/B2 thymoma with positive acetylcholine receptor antibodies but without myasthenia/Video. Tibor Krajc, Department of Thoracic Surgery, Klinik Floridsdorf Vienna, Austria

Poster #21: Histopathologic characteristics of resected thymic cyst walls, with imaging correlation. Julian A. Villalba, James Homer Wright Pathology Laboratories, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

12:45 – 13:00 EST/EDT

Break

13:00 – 14:00 EST/EDT

PLENARY SESSION

Chair/Moderator: 

Frank Detterbeck, The Yale University School of Medicine, New Haven, CT, USA

ITMIG Prospective Database – a worldwide project for thymic tumors

Nicolas Girard, The Institut Curie, Paris, France (15 min)


Advances in thoracic surgery for thymic tumors

Jens Ruckert, Competence Center for Thoracic Surgery, Surgical Clinic of the University Medicine Berlin (Charité), Berlin, Germany (15 min)


Advances in systemic therapy for thymic tumors

Patrick Loehrer, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, USA (15 min)


Live Q&A

TIME (EST/EDT)

EST = Eastern Standard Time

EDT = Eastern Daylight Time

SATURDAY, OCTOBER 16, 2021

08:30 – 08:40 EST/EDT 

Opening of a conference

08:40 – 09:50 EST/EDT 

Session 1: The small mediastinal lesion and early-stage thymic tumor

Chairs/Moderators: 

Paul Van Schil, The Antwerp University Hospital and Antwerp University, Department of Thoracic and Vascular Surgery, Edegem (Antwerp), Belgium

Charles Simone, The Memorial Sloan Kettering Cancer Center and New York Proton Center, New York, USA


Imaging the small mediastinal lesion

Edith Marom, The Chaim Sheba Medical Center, Ramat Gan, Israel (15 min)


The small mediastinal lesion – management options

Joshua Sonett, The Columbia University/New York-Presbyterian Hospital, New York City, USA (15 min)


Thymomectomy or complete thymectomy of early-stage thymic tumor: Thymomectomy is sufficient

Wentao Fang, The Shanghai Chest Hospital, Shanghai, China (10 min)


Thymomectomy or complete thymectomy of early-stage thymic tumor: Complete thymectomy is more effective

Marlies Keijzers, The Maastricht University Medical Center, Maastricht, The Netherlands (10 min)

Oral Abstract Presentations

Robotic thymectomy for thymomas: a retrospective follow-up study in the Netherlands, Florit Marcuse, Department of Pulmonology, Maastricht University Medical Center+, Maastricht, the Netherlands (10 min)

Optimal delineation of the clinical target volume for thymomas in the postoperative setting: a multi-center study, Florit Marcuse, Department of Pulmonology, Maastricht University Medical Center+, Maastricht, the Netherlands (10 min)

09:50 – 10:20 EST/EDT 

Live Q&A

10:20 – 10:40 EST/EDT

Break

10:40 – 12:05 EST/EDT 

Session 2: Thymic tumors and clinical correlates (part 1):

Neurological comorbidities, TETs in children

Chair/Moderator: Giuseppe Cardillo, Thoracic Surgery, Azienda Ospedaliera San Camillo Forlanini, Rome, Italy


Paraneoplastic syndromes associated with thymoma beyond myasthenia gravis

Berthold Schalke, Neurologische Klinik und Poliklinik der Universität Regensburg, Regensburg, Germany (15 min)


Multidisciplinary approach to pre- and post-thymectomy care of thymoma patients

Anna Kostera-Pruszczyk, The Medical University of Warsaw, Central University Hospital, Warsaw, Poland (15 min)


Clinical and laboratory features heralding the appearance of thymomas

Mohammad Ashraghi, The Nuffield Department of Clinical Neurosciences, The John Radcliffe Hospital, Oxford, UK (15 min)


Clinical workup of the asymptomatic patient with suspected thymoma

Alper Toker, The West Virginia University Heart and Vascular Institute, Morgantown, WV, USA (15 min)


Thymic tumors in children

Daniel Orbach, The Institut Curie, SIREDO Oncology Center, Paris, France (15 min)

Oral Abstract Presentation

Subclinical myasthenia gravis in thymomas, Florit Marcuse, Department of Pulmonology, Maastricht University Medical Center+, Maastricht, the Netherlands (10 min)

12:05 – 12:35 EST/EDT 

Live Q&A

12:35 – 13:05 EST/EDT

Break

13:05 – 14:30 EST/EDT 

Session 3: Thymic tumors and clinical correlates (part 2):

Thymic pathology and SARS-CoV-2 infection

Chair/Moderator: Sukhmani Padda, The Cedars-Sinai Medical Center, Los Angeles, USA


Thymic pathology in COVID-19 patients

Amira Marouf, Critical Care Medicine & Clinical Research Departments, Clinique Ambroise Paré, Neuilly Sur Seine, France (15 min)


COVID-19 in patients with myasthenia gravis

Richard Nowak, The Department of Neurology, The Yale School of Medicine, New Haven, CT, USA (15 min)


Effect of SARS-CoV-2 epidemic on the management of thymic tumor patients

Alan Kirk, Golden Jubilee National Hospital, Clydebank, Scotland, United Kingdom (15 min)

Oral Abstract Presentations

Preliminary data of immunogenicity of SARS-COV-2 mRNA vaccine in Thymic Epithelial Tumors, Erica Pietroluongo, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy (10 min)

Tolerability of COVID-19 mRNA Vaccines in Patients with Thymic Epithelial Tumors, Madison Ballman, Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA (10 min)

Molecular Profiling of Genetic Alterations in Thymic Epithelial Tumors by Targeted Next Generation Sequencing – A Pilot Study, Adam Szpechcinski, Department of Genetics and Clinical Immunology, The National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland (10 min)

Different pattern of IDO 1 and PD-L1 immunoexpression in Thymomas, Surabhi Jain, Department of Pathology, All India Institute of Medical Sciences, New Delhi, India (10 min)

14:30 – 15:00 EST/EDT 

Live Q&A

TIME (EST/EDT)

EST = Eastern Standard Time

EDT = Eastern Daylight Time

SUNDAY, OCTOBER 17, 2021

08:30 – 09:50 EST/EDT  

Session 4: Metastatic pleural disease in the course of TETs – multidisciplinary approach

Chair/Moderator: Andreas Rimner, Memorial Sloan Kettering Cancer Center, New York, USA


Cases presentation – what strategy do you propose? (I-st voting)

Conrad Falkson, The Queen’s University and Kingston Health Sciences Center, Kingston, Ontario, Canada (15 min)


Imaging of metastatic pleural dissemination

Jeanne Ackman, Harvard Medical School, Massachusetts General Hosptial, Boston, MA, USA (15 min)


Surgical options for treatment of metastatic pleural disease

Meinoshin Okumura, The National Hospital Organization, The Osaka Toneyama Medical Center, Toyonaka, Japan (15 min)


Radiation strategy and technics for metastatic pleural disease

Annemarie Shepherd, The Memorial Sloan Kettering Cancer Center, New York City, NY, USA (15 min)


When to observe and when to start systemic therapy? Systemic treatment options for metastatic pleural disease

Gregory Riely, The Memorial Sloan Kettering Cancer Center, New York, USA (15 min)


Cases presentation – re-evaluation. What strategy do you propose now? (II-nd voting)

Conrad Falkson, The Queen’s University and Kingston Health Sciences Center, Kingston, Ontario, Canada  (5 min)

09:50 – 10:20 EST/EDT 

Live Q&A

10:20 – 10:50 EST/EDT

Break

10:50 – 12:10 EST/EDT 

Session 5: Updates in mediastinal tumors classifications:

TNM 8th Ed.,

WHO 2021 histological classification

Mediastinal compartments/CT

Chair/Moderator: Enrico Ruffini, The University of Torino, Torino, Italy


TNM 8th. Ed. staging of TETs – UPDATE – Pathologist’s perspective

Thierry Molina, The APHP, The University of Paris, Robert Debré and Necker Enfants Malades Hospitals, Paris, France (10 min)


TNM 8th. Ed. staging of TETs – UPDATE – Surgeon’s perspective

Dong Kwan Kim, The Asan Medical Center, Seoul, KOREA (10 min)


TNM 8th. Ed. staging of TETs – UPDATE – Medical oncologist’s perspective

Nicolas Girard, The Institut Curie, Paris, France (10 min)


TNM 8th. Ed. staging of TETs – UPDATE – Radiation oncologist’s perspective

Abigail Berman, University of Pennsylvania Health System, Philadelphia, PA, USA (10 min)


WHO 2021 histological classification for mediastinal tumors

Alexander Marx, The Institute of Pathology, The University Medical Centre Mannheim, The University of Heidelberg, Mannheim, Germany (10 min)


ITMIG classification (CT-based) of mediastinal compartments

Brett Carter, MD Anderson Cancer Center, Houston, Texas, USA (10 min)

Oral Abstract Presentations

Importance of an international refining of histopathological criteria of pT in Thymic Epithelial Tumors: a RYTHMIC/ITMIG study, Thierry Molina, Pathology, University of Paris, Necker Enfants Malades and Robert Debre Hospitals, APHP, Paris (10 min)

Transcriptional and chromatin profiling reveals the molecular architecture and druggable vulnerabilities of TETs, Pierluigi Manti, Department of Experimental Oncology, IEO, European Institute of Oncology, IRCCS, Milan, Italy (10 min)

12:10 – 12:40 EST/EDT 

Live Q&A

12:40 – 13:10 EST/EDT

Break

13:10 – 13:50 EST/EDT 

Session 6: Thymic carcinomas vs. lung carcinomas

Chair/Moderator: James Huang, The Memorial Sloan Kettering Cancer Center, New York, USA


Thymic carcinomas vs. lung carcinomas – Radiologist’s perspective

Chad Strange, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA (10 min)


Thymic carcinomas vs. lung carcinomas – Pathologist’s perspective

Malgorzata Szolkowska, The National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland (10 min)


Thymic carcinomas vs. lung carcinomas – Surgeon’s perspective

Frank Detterbeck, The Yale University School of Medicine, New Haven, CT, USA (10 min)


Thymic carcinomas vs. lung carcinomas – Medical oncologist’s perspective

Arun Rajan, The National Cancer Institute, The National Institutes of Health (NCI/NIH), Bethesda, USA (10 min)

13:50 – 14:10 EST/EDT 

Live Q&A

14:10 – 14:50 EST/EDT 

Live Tumor Board: presentation of a case of advance thymic epithelial tumor

Presenter: Marcin Zielinski, The Pulmonary Hospital “Odrodzenie” of the name of Klara Jelska, Zakopane, Poland (10 min)

Experts panel:

Anja Roden, The Mayo Clinic Rochester, Rochester, MN, USA

Mylene Truong

Dirk Van Raemdonck, University Hospital Gasthuisberg, Leuven, Belgium

Ritsuko Komaki, Baylor College of Medicine in Houston TX, USA

Heather Wakelee, Stanford University, Stanford, CA, USA

14:50 – 15:00 EST/EDT 

Closing of a conference